MedTrace Logo

Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use

NCT04181515 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-04-13

No results posted yet for this study

Summary

This study will use a stress (vs. placebo) exposure model, paired with single-session sham vs. active rTMS at two distinct cortical locations (dlPFC vs. mPFC in parallel groups) to assess whether rTMS neuromodulation at these alternative loci differentially influence stress-reactivity and opioid reinforcement in non-treatment seeking participants with OUD. Stress-reactivity will be measured using cognitive, affective, behavioral and biological phenotypes.

Conditions

  • Stress
  • Opioid-use Disorder

Interventions

DRUG

Placebo oral tablet

placebo stressor

DRUG

Yohimbine + Hydrocortisone

Yohimbine 54mg + Hydrocortisone 20mg

DEVICE

sham rTMS

sham rTMS (inactive coil)

DEVICE

active rTMS

active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Mark Greenwald, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2023-04-10
Completion
2023-04-10
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04181515 on ClinicalTrials.gov